Director, See Remarks · Opus Genetics, Inc. · Common Stock
Side
SELL
Value
$2.76M
Shares
556.0K
Price
$4.96
Executed
Sep 30, 2026
Disclosed
Oct 2, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Sep 30 executedOct 2, 2026 disclosed
IRD · daily
Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.
Disclosed 2 business days after execution (deadline: 2)
Historical behavior+4 / 15
2 prior trades recorded in this security
Frequency & clustering0 / 15
No clustered activity in the dataset
Market events0 / 10
No material company filing within 60 days after the trade
The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.
Foundation Fighting Blindness Retinal Degeneration Fund
Role
Director, See Remarks
Transaction
Open-market saleAs filed: “S”
Asset
Opus Genetics, Inc.
Ticker
IRD
Shares
556.0K
Price per share
$4.96
Value
$2,755,981
Execution date (reported)
Sep 30, 2026
Owned after transaction
3.24M shares
Days from execution to publication
2
Calculation
Value = shares × reported price per share
Shares: 556.0K
Price: $4.9568
= $2,755,981
What this establishes
Foundation Fighting Blindness Retinal Degeneration Fund filed this Form 4 reporting a open-market sale of IRD on Sep 30, 2026. It became public on Oct 2, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.
Extraction
Method
Form 4 XML
Confidence
1.00
Director, See Remarks
Foundation Fighting Blindness Retinal Degeneration Fundcik:0002042266
Issuer
Opus Genetics, Inc.cik:0001228627
Revision history · 0
No field has changed since this record was first ingested.
IRDOpus Genetics, Inc.